Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 153

1.

Apolipoprotein B, Triglyceride-Rich Lipoproteins, and Risk of Cardiovascular Events in Persons with CKD.

Lamprea-Montealegre JA, Staplin N, Herrington WG, Haynes R, Emberson J, Baigent C, de Boer IH; SHARP Collaborative Group.

Clin J Am Soc Nephrol. 2020 Jan 7;15(1):47-60. doi: 10.2215/CJN.07320619. Epub 2019 Dec 12.

PMID:
31831577
2.

Autopsy as a form of evisceration: Implications for decomposition rate, pattern, and estimation of postmortem interval.

Baigent C, Agan C, Connor M, Hansen ES.

Forensic Sci Int. 2020 Jan;306:110068. doi: 10.1016/j.forsciint.2019.110068. Epub 2019 Nov 19.

PMID:
31816485
3.

The Scavenging Patterns of Feral Cats on Human Remains in an Outdoor Setting.

Garcia S, Smith A, Baigent C, Connor M.

J Forensic Sci. 2019 Nov 8. doi: 10.1111/1556-4029.14238. [Epub ahead of print]

PMID:
31703159
4.

2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.

Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, Chapman MJ, De Backer GG, Delgado V, Ference BA, Graham IM, Halliday A, Landmesser U, Mihaylova B, Pedersen TR, Riccardi G, Richter DJ, Sabatine MS, Taskinen MR, Tokgozoglu L, Wiklund O; ESC Scientific Document Group .

Eur Heart J. 2020 Jan 1;41(1):111-188. doi: 10.1093/eurheartj/ehz455. No abstract available.

PMID:
31504418
5.

Variability in aspirin efficacy: all in the genes?

Baigent C, Holmes MV.

Eur Heart J. 2019 Nov 1;40(41):3393-3396. doi: 10.1093/eurheartj/ehz456. No abstract available.

6.

Role of aspirin in primary prevention of cardiovascular disease.

Patrono C, Baigent C.

Nat Rev Cardiol. 2019 Nov;16(11):675-686. doi: 10.1038/s41569-019-0225-y. Epub 2019 Jun 26. Review.

PMID:
31243390
7.

Chronic kidney disease, heart failure and neprilysin inhibition.

Haynes R, Zhu D, Judge PK, Herrington WG, Kalra PA, Baigent C.

Nephrol Dial Transplant. 2019 Apr 26. pii: gfz058. doi: 10.1093/ndt/gfz058. [Epub ahead of print]

PMID:
31028383
8.

Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease.

Schlackow I, Kent S, Herrington W, Emberson J, Haynes R, Reith C, Collins R, Landray MJ, Gray A, Baigent C, Mihaylova B; SHARP Collaborative Group.

Kidney Int. 2019 Jul;96(1):170-179. doi: 10.1016/j.kint.2019.01.028. Epub 2019 Mar 12.

9.

Measuring Desiccation Using Qualitative Changes: A Step Toward Determining Regional Decomposition Sequences.

Connor M, Baigent C, Hansen ES.

J Forensic Sci. 2019 Jul;64(4):1004-1011. doi: 10.1111/1556-4029.14003. Epub 2019 Jan 21.

PMID:
30664795
10.

The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study.

Herrington WG, Preiss D, Haynes R, von Eynatten M, Staplin N, Hauske SJ, George JT, Green JB, Landray MJ, Baigent C, Wanner C.

Clin Kidney J. 2018 Dec;11(6):749-761. doi: 10.1093/ckj/sfy090. Epub 2018 Oct 25. Review.

11.

Effects of n-3 Fatty Acid Supplements in Diabetes Mellitus.

ASCEND Study Collaborative Group, Bowman L, Mafham M, Wallendszus K, Stevens W, Buck G, Barton J, Murphy K, Aung T, Haynes R, Cox J, Murawska A, Young A, Lay M, Chen F, Sammons E, Waters E, Adler A, Bodansky J, Farmer A, McPherson R, Neil A, Simpson D, Peto R, Baigent C, Collins R, Parish S, Armitage J.

N Engl J Med. 2018 Oct 18;379(16):1540-1550. doi: 10.1056/NEJMoa1804989. Epub 2018 Aug 26.

12.

Effects of Aspirin for Primary Prevention in Persons with Diabetes Mellitus.

ASCEND Study Collaborative Group, Bowman L, Mafham M, Wallendszus K, Stevens W, Buck G, Barton J, Murphy K, Aung T, Haynes R, Cox J, Murawska A, Young A, Lay M, Chen F, Sammons E, Waters E, Adler A, Bodansky J, Farmer A, McPherson R, Neil A, Simpson D, Peto R, Baigent C, Collins R, Parish S, Armitage J.

N Engl J Med. 2018 Oct 18;379(16):1529-1539. doi: 10.1056/NEJMoa1804988. Epub 2018 Aug 26.

13.

Effects of Sacubitril/Valsartan Versus Irbesartan in Patients With Chronic Kidney Disease.

Haynes R, Judge PK, Staplin N, Herrington WG, Storey BC, Bethel A, Bowman L, Brunskill N, Cockwell P, Hill M, Kalra PA, McMurray JJV, Taal M, Wheeler DC, Landray MJ, Baigent C.

Circulation. 2018 Oct 9;138(15):1505-1514. doi: 10.1161/CIRCULATIONAHA.118.034818.

PMID:
30002098
14.

Impact of CKD on Household Income.

Morton RL, Schlackow I, Gray A, Emberson J, Herrington W, Staplin N, Reith C, Howard K, Landray MJ, Cass A, Baigent C, Mihaylova B; SHARP Collaborative Group.

Kidney Int Rep. 2017 Dec 23;3(3):610-618. doi: 10.1016/j.ekir.2017.12.008. eCollection 2018 May.

15.

Fibroblast Growth Factor-23 and Risks of Cardiovascular and Noncardiovascular Diseases: A Meta-Analysis.

Marthi A, Donovan K, Haynes R, Wheeler DC, Baigent C, Rooney CM, Landray MJ, Moe SM, Yang J, Holland L, di Giuseppe R, Bouma-de Krijger A, Mihaylova B, Herrington WG.

J Am Soc Nephrol. 2018 Jul;29(7):2015-2027. doi: 10.1681/ASN.2017121334. Epub 2018 May 15. Review.

16.

Effect of diabetes duration and glycaemic control on 14-year cause-specific mortality in Mexican adults: a blood-based prospective cohort study.

Herrington WG, Alegre-Díaz J, Wade R, Gnatiuc L, Ramirez-Reyes R, Hill M, Solano-Sánchez M, Baigent C, Lewington S, Collins R, Tapia-Conyer R, Peto R, Kuri-Morales P, Emberson JR.

Lancet Diabetes Endocrinol. 2018 Jun;6(6):455-463. doi: 10.1016/S2213-8587(18)30050-0. Epub 2018 Mar 19.

17.

Antithrombotic therapy and body mass: an expert position paper of the ESC Working Group on Thrombosis.

Rocca B, Fox KAA, Ajjan RA, Andreotti F, Baigent C, Collet JP, Grove EL, Halvorsen S, Huber K, Morais J, Patrono C, Rubboli A, Seljeflot I, Sibbing D, Siegbahn A, Ten Berg J, Vilahur G, Verheugt FWA, Wallentin L, Weiss TW, Wojta J, Storey RF.

Eur Heart J. 2018 May 14;39(19):1672-1686f. doi: 10.1093/eurheartj/ehy066. No abstract available.

PMID:
29509886
18.

Effects of gastroprotectant drugs for the prevention and treatment of peptic ulcer disease and its complications: a meta-analysis of randomised trials.

Scally B, Emberson JR, Spata E, Reith C, Davies K, Halls H, Holland L, Wilson K, Bhala N, Hawkey C, Hochberg M, Hunt R, Laine L, Lanas A, Patrono C, Baigent C.

Lancet Gastroenterol Hepatol. 2018 Apr;3(4):231-241. doi: 10.1016/S2468-1253(18)30037-2. Epub 2018 Feb 21.

19.

Impact of Apolipoprotein(a) Isoform Size on Lipoprotein(a) Lowering in the HPS2-THRIVE Study.

Parish S, Hopewell JC, Hill MR, Marcovina S, Valdes-Marquez E, Haynes R, Offer A, Pedersen TR, Baigent C, Collins R, Landray M, Armitage J; HPS2-THRIVE Collaborative Group.

Circ Genom Precis Med. 2018 Feb;11(2):e001696. doi: 10.1161/CIRCGEN.117.001696.

20.

Declining comorbidity-adjusted mortality rates in English patients receiving maintenance renal replacement therapy.

Storey BC, Staplin N, Harper CH, Haynes R, Winearls CG, Goldacre R, Emberson JR, Goldacre MJ, Baigent C, Landray MJ, Herrington WG.

Kidney Int. 2018 May;93(5):1165-1174. doi: 10.1016/j.kint.2017.11.020. Epub 2018 Feb 12.

21.

The role of lipoprotein (a) in chronic kidney disease.

Hopewell JC, Haynes R, Baigent C.

J Lipid Res. 2018 Apr;59(4):577-585. doi: 10.1194/jlr.R083626. Epub 2018 Jan 29. Review.

22.

Should We Increase GFR with Bardoxolone in Alport Syndrome?

Baigent C, Lennon R.

J Am Soc Nephrol. 2018 Feb;29(2):357-359. doi: 10.1681/ASN.2017101062. Epub 2018 Jan 25. No abstract available.

23.

Testing the Use of Pigs as Human Proxies in Decomposition Studies.

Connor M, Baigent C, Hansen ES.

J Forensic Sci. 2018 Sep;63(5):1350-1355. doi: 10.1111/1556-4029.13727. Epub 2017 Dec 28.

PMID:
29284073
24.

Effects of alteplase for acute stroke according to criteria defining the European Union and United States marketing authorizations: Individual-patient-data meta-analysis of randomized trials.

Hacke W, Lyden P, Emberson J, Baigent C, Blackwell L, Albers G, Bluhmki E, Brott T, Cohen G, Davis SM, Donnan GA, Grotta JC, Howard G, Kaste M, Koga M, von Kummer R, Lansberg MG, Lindley RI, Olivot JM, Parsons M, Sandercock PA, Toni D, Toyoda K, Wahlgren N, Wardlaw JM, Whiteley WN, Del Zoppo G, Lees KR; Stroke Thrombolysis Trialists’ Collaborators Group.

Int J Stroke. 2018 Feb;13(2):175-189. doi: 10.1177/1747493017744464. Epub 2017 Nov 24. Erratum in: Int J Stroke. 2018 Feb;13(2):NP3.

PMID:
29171359
25.

Lowering LDL cholesterol reduces cardiovascular risk independently of presence of inflammation.

Storey BC, Staplin N, Haynes R, Reith C, Emberson J, Herrington WG, Wheeler DC, Walker R, Fellström B, Wanner C, Landray MJ, Baigent C; SHARP Collaborative Group.

Kidney Int. 2018 Apr;93(4):1000-1007. doi: 10.1016/j.kint.2017.09.011. Epub 2017 Nov 14.

26.

Bioelectrical Impedance as a Technique for Estimating Postmortem Interval,.

Hansen ES, Baigent C, Reck SI, Connor M.

J Forensic Sci. 2018 Jul;63(4):1186-1190. doi: 10.1111/1556-4029.13695. Epub 2017 Nov 16.

PMID:
29143324
27.

Antiplatelet Agents for the Treatment and Prevention of Coronary Atherothrombosis.

Patrono C, Morais J, Baigent C, Collet JP, Fitzgerald D, Halvorsen S, Rocca B, Siegbahn A, Storey RF, Vilahur G.

J Am Coll Cardiol. 2017 Oct 3;70(14):1760-1776. doi: 10.1016/j.jacc.2017.08.037. Review.

28.

A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease.

Schlackow I, Kent S, Herrington W, Emberson J, Haynes R, Reith C, Wanner C, Fellström B, Gray A, Landray MJ, Baigent C, Mihaylova B; SHARP Collaborative Group.

Heart. 2017 Dec;103(23):1880-1890. doi: 10.1136/heartjnl-2016-310970. Epub 2017 Aug 5.

29.

Challenges in conducting clinical trials in nephrology: conclusions from a Kidney Disease-Improving Global Outcomes (KDIGO) Controversies Conference.

Baigent C, Herrington WG, Coresh J, Landray MJ, Levin A, Perkovic V, Pfeffer MA, Rossing P, Walsh M, Wanner C, Wheeler DC, Winkelmayer WC, McMurray JJV; KDIGO Controversies Conference on Challenges in the Conduct of Clinical Trials in Nephrology Conference Participants.

Kidney Int. 2017 Aug;92(2):297-305. doi: 10.1016/j.kint.2017.04.019.

30.

Cardiovascular disease: PCSK9 inhibition: a new player in cholesterol-lowering therapies?

Preiss D, Baigent C.

Nat Rev Nephrol. 2017 Aug;13(8):450-451. doi: 10.1038/nrneph.2017.94. Epub 2017 Jul 3. No abstract available.

PMID:
28669994
31.

Biliary Tract and Liver Complications in Polycystic Kidney Disease.

Judge PK, Harper CHS, Storey BC, Haynes R, Wilcock MJ, Staplin N, Goldacre R, Baigent C, Collier J, Goldacre M, Landray MJ, Winearls CG, Herrington WG.

J Am Soc Nephrol. 2017 Sep;28(9):2738-2748. doi: 10.1681/ASN.2017010084. Epub 2017 May 2.

32.

Effect on non-vascular outcomes of lowering LDL cholesterol in patients with chronic kidney disease: results from the Study of Heart and Renal Protection.

Reith C, Staplin N, Herrington WG, Stevens W, Emberson J, Haynes R, Mafham M, Armitage J, Cass A, Craig JC, Jiang L, Pedersen T, Baigent C, Landray MJ; SHARP Collaborative Group.

BMC Nephrol. 2017 May 1;18(1):147. doi: 10.1186/s12882-017-0545-2.

33.

Coxibs, Traditional NSAIDs, and Cardiovascular Safety Post-PRECISION: What We Thought We Knew Then and What We Think We Know Now.

Patrono C, Baigent C.

Clin Pharmacol Ther. 2017 Aug;102(2):238-245. doi: 10.1002/cpt.696. Epub 2017 May 26. Review.

PMID:
28378879
34.

Safety and efficacy of statins - Authors' reply.

Collins R, Armitage J, Baigent C, Smith GD, Smeeth L.

Lancet. 2017 Mar 18;389(10074):1099-1100. doi: 10.1016/S0140-6736(17)30717-1. No abstract available.

PMID:
28322816
35.

Prognostic utility of estimated albumin excretion rate in chronic kidney disease: results from the Study of Heart and Renal Protection.

Mafham MM, Staplin N, Emberson J, Haynes R, Herrington W, Reith C, Wanner C, Walker R, Cass A, Levin A, Fellström B, Jiang L, Holdaas H, Kasiske B, Wheeler DC, Landray MJ, Baigent C; SHARP Collaborative Group.

Nephrol Dial Transplant. 2018 Feb 1;33(2):257-264. doi: 10.1093/ndt/gfw396.

36.

Evidence for Reverse Causality in the Association Between Blood Pressure and Cardiovascular Risk in Patients With Chronic Kidney Disease.

Herrington W, Staplin N, Judge PK, Mafham M, Emberson J, Haynes R, Wheeler DC, Walker R, Tomson C, Agodoa L, Wiecek A, Lewington S, Reith CA, Landray MJ, Baigent C; SHARP Collaborative Group.

Hypertension. 2017 Feb;69(2):314-322. doi: 10.1161/HYPERTENSIONAHA.116.08386. Epub 2016 Dec 27.

37.

Diabetes and Cause-Specific Mortality in Mexico City.

Alegre-Díaz J, Herrington W, López-Cervantes M, Gnatiuc L, Ramirez R, Hill M, Baigent C, McCarthy MI, Lewington S, Collins R, Whitlock G, Tapia-Conyer R, Peto R, Kuri-Morales P, Emberson JR.

N Engl J Med. 2016 Nov 17;375(20):1961-1971. doi: 10.1056/NEJMoa1605368.

38.

Are statins useful in patients with advanced chronic kidney disease? - Authors' reply.

Herrington WG, Emberson J, Mihaylova B, Collins R, Baigent C; Cholesterol Treatment Trialists' Collaboration.

Lancet Diabetes Endocrinol. 2016 Dec;4(12):971-972. doi: 10.1016/S2213-8587(16)30266-2. No abstract available.

PMID:
27886746
39.

Lessons from the controversy over statins - Authors' reply.

Armitage J, Baigent C, Collins R.

Lancet. 2016 Nov 5;388(10057):2237-2238. doi: 10.1016/S0140-6736(16)32075-X. No abstract available.

PMID:
27825506
40.

Effect of Processing Delay and Storage Conditions on Urine Albumin-to-Creatinine Ratio.

Herrington W, Illingworth N, Staplin N, Kumar A, Storey B, Hrusecka R, Judge P, Mahmood M, Parish S, Landray M, Haynes R, Baigent C, Hill M, Clark S.

Clin J Am Soc Nephrol. 2016 Oct 7;11(10):1794-1801. doi: 10.2215/CJN.13341215. Epub 2016 Sep 21.

41.

Interpretation of the evidence for the efficacy and safety of statin therapy.

Collins R, Reith C, Emberson J, Armitage J, Baigent C, Blackwell L, Blumenthal R, Danesh J, Smith GD, DeMets D, Evans S, Law M, MacMahon S, Martin S, Neal B, Poulter N, Preiss D, Ridker P, Roberts I, Rodgers A, Sandercock P, Schulz K, Sever P, Simes J, Smeeth L, Wald N, Yusuf S, Peto R.

Lancet. 2016 Nov 19;388(10059):2532-2561. doi: 10.1016/S0140-6736(16)31357-5. Epub 2016 Sep 8. Review. Erratum in: Lancet. 2017 Feb 11;389(10069):602.

42.

Use of Causal Diagrams to Inform the Design and Interpretation of Observational Studies: An Example from the Study of Heart and Renal Protection (SHARP).

Staplin N, Herrington WG, Judge PK, Reith CA, Haynes R, Landray MJ, Baigent C, Emberson J.

Clin J Am Soc Nephrol. 2017 Mar 7;12(3):546-552. doi: 10.2215/CJN.02430316. Epub 2016 Aug 23.

43.

Effects of Alteplase for Acute Stroke on the Distribution of Functional Outcomes: A Pooled Analysis of 9 Trials.

Lees KR, Emberson J, Blackwell L, Bluhmki E, Davis SM, Donnan GA, Grotta JC, Kaste M, von Kummer R, Lansberg MG, Lindley RI, Lyden P, Murray GD, Sandercock PA, Toni D, Toyoda K, Wardlaw JM, Whiteley WN, Baigent C, Hacke W, Howard G; Stroke Thrombolysis Trialists’ Collaborators Group.

Stroke. 2016 Sep;47(9):2373-9. doi: 10.1161/STROKEAHA.116.013644. Epub 2016 Aug 9.

44.

Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials.

Cholesterol Treatment Trialists' (CTT) Collaboration, Herrington WG, Emberson J, Mihaylova B, Blackwell L, Reith C, Solbu MD, Mark PB, Fellström B, Jardine AG, Wanner C, Holdaas H, Fulcher J, Haynes R, Landray MJ, Keech A, Simes J, Collins R, Baigent C.

Lancet Diabetes Endocrinol. 2016 Oct;4(10):829-39. doi: 10.1016/S2213-8587(16)30156-5. Epub 2016 Jul 29.

45.

Chronic kidney disease and the risk of cancer: an individual patient data meta-analysis of 32,057 participants from six prospective studies.

Wong G, Staplin N, Emberson J, Baigent C, Turner R, Chalmers J, Zoungas S, Pollock C, Cooper B, Harris D, Wang JJ, Mitchell P, Prince R, Lim WH, Lewis J, Chapman J, Craig J.

BMC Cancer. 2016 Jul 16;16:488. doi: 10.1186/s12885-016-2532-6.

46.

Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysis.

Whiteley WN, Emberson J, Lees KR, Blackwell L, Albers G, Bluhmki E, Brott T, Cohen G, Davis S, Donnan G, Grotta J, Howard G, Kaste M, Koga M, von Kummer R, Lansberg MG, Lindley RI, Lyden P, Olivot JM, Parsons M, Toni D, Toyoda K, Wahlgren N, Wardlaw J, Del Zoppo GJ, Sandercock P, Hacke W, Baigent C; Stroke Thrombolysis Trialists' Collaboration.

Lancet Neurol. 2016 Aug;15(9):925-933. doi: 10.1016/S1474-4422(16)30076-X. Epub 2016 Jun 8.

PMID:
27289487
47.

The Safety and Efficacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta-analysis.

Quach K, Lvtvyn L, Baigent C, Bueti J, Garg AX, Hawley C, Haynes R, Manns B, Perkovic V, Rabbat CG, Wald R, Walsh M.

Am J Kidney Dis. 2016 Oct;68(4):591-598. doi: 10.1053/j.ajkd.2016.04.011. Epub 2016 Jun 3. Review.

48.

Advances and unmet needs in genetic, basic and clinical science in Alport syndrome: report from the 2015 International Workshop on Alport Syndrome.

Gross O, Kashtan CE, Rheault MN, Flinter F, Savige J, Miner JH, Torra R, Ars E, Deltas C, Savva I, Perin L, Renieri A, Ariani F, Mari F, Baigent C, Judge P, Knebelman B, Heidet L, Lagas S, Blatt D, Ding J, Zhang Y, Gale DP, Prunotto M, Xue Y, Schachter AD, Morton LCG, Blem J, Huang M, Liu S, Vallee S, Renault D, Schifter J, Skelding J, Gear S, Friede T, Turner AN, Lennon R.

Nephrol Dial Transplant. 2017 Jun 1;32(6):916-924. doi: 10.1093/ndt/gfw095.

49.

Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP).

Staplin N, Haynes R, Herrington WG, Reith C, Cass A, Fellström B, Jiang L, Kasiske BL, Krane V, Levin A, Walker R, Wanner C, Wheeler DC, Landray MJ, Baigent C, Emberson J; SHARP Collaborative Group.

Am J Kidney Dis. 2016 Sep;68(3):371-80. doi: 10.1053/j.ajkd.2016.02.052. Epub 2016 Apr 23.

50.

Aspirin for Disease Prevention: Public Policy or Personal Choice?

Baigent C.

Ann Intern Med. 2016 Jun 21;164(12):846-7. doi: 10.7326/M16-0576. Epub 2016 Apr 12. No abstract available.

PMID:
27064970

Supplemental Content

Loading ...
Support Center